| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT06144710 SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
Trial completed |
| 2026-08-12 | NCT06144710 SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
date change Completion moved earlier: 2026-10-24 -> 2026-01-07 |
| 2026-08-12 | NCT04684108 SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other… |
date change Completion pushed: 2026-06-30 -> 2026-12-30 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-14 | NCT07764627 Study of SG301 for Renal AMR After Transplantation | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06508983 | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus… | Relapsed/Refractory Multiple Myeloma | Recruiting |
| Phase 2 | |||
| NCT07447986 | To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT07710248 | SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Primary Immune Thrombocytopenia | Recruiting |
| NCT07764627 | Study of SG301 for Renal AMR After Transplantation | Antibody Mediated Rejection | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | Recruiting |
| Phase 1 | |||
| NCT05857332 | SG1906 for CLDN18.2-Positive Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting |
| NCT06076291 | An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors | Advanced Solid Tumors | Active, Not Recruiting |
| NCT04684108 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other… | Relapsed or Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT06167486 | SG2918 For Advanced Malignant Tumors | Advanced Malignant Tumors | Active, Not Recruiting |